62 results about "Biological response modifiers" patented technology

The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by controlled and directed delivery of one or more biological response modifiers to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by implantable or infusion pumps, implantable controlled release devices, or by sustained release compositions comprising biological response modifiers.

The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.

The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by controlled and directed delivery of one or more biological response modifiers to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by implantable or infusion pumps, implantable controlled release devices, or by sustained release compositions comprising biological response modifiers.

Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.

A biosensor for detection of vascular endothelial growth factor (VEGF) hybridization uses an array of parallel capacitors to detect electrochemical binding of circulating VEGF to immobilized anti-VEGF monoclonal half-antibodies (a-VEGF mhAb). Binding of a-VEGF mhAb modulates the threshold voltage of a circuit, changing the impedance of the circuit. An electrode coated with a p-Si substrate enhances the affinity between the VEGF molecules. A fluid cell delivers VEGF samples onto the active surface of the chip. An array of parallel capacitors arranged in an interdigitated pattern detects the VEGF in the fluid. The detector provides an accurately measured and quantifiable rate of change of the VEGF molecules in vivo, providing real time feedback which is used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden and efficacy of the chemotherapy as part of a homeostatic loop for chemotherapy.

Embodiments of the present invention relate to multicistronic vectors and methods for their design. Methods and compositions of the invention include a vector including at least two cistrons, wherein a first cistron includes a first promoter and a first nucleic acid sequence encoding one or more therapeutic agents, and wherein a second cistron comprises a second promoter and a second nucleic acid sequence encoding one or more RNA molecules that interfere with the expression of a biological response modifier or the therapeutic agent, wherein the expression of the first sequence is under control of the first promoter and expression of the second sequence is under control of the second promoter.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested / shown that C20:5n-3 (and C22:6 n-3) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula:wherein:X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S;R1 is selected from a member of the group consisting of hydrogen, methyl, C(5-9)alkyl, C(5-9)alkenyl, C(5-9)alkynyl, C(5-9)hydroxyalkyl, C(3-8)alkoxyl, C(5-9)alkoxyalkyl, the R1 being optionally substituted;R2 and R3 are independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.

The invention relates to a method for preparing anti-aging steamed bread. The method concretely comprises the following operation steps: (1) preparing an activated yeast solution; (2) modulating paste, namely, mixing and stirring special flour for steamed bread with beta-glucan, and adding the yeast solution to obtain smooth and intact paste; (3) fermenting and molding for the second time; (4) steaming by steam to obtain the steamed bread; (5) packaging and storing, cooling and bagging at room temperature, and storing at room temperature. The method provided by the invention not only is simple and feasible, but also the aging of the steamed bread is inhibited and the shelf life of the steamed bread is prolonged to be over 6 days at the room temperature by the water-retaining property, the gelling property and the antibacterial activity of the beta-glucan. On the other hand, the beta-glucan is a biological response modifier, and has a plurality of physiological active functions of enhancing the immunity of the organism and the like, and the health quality of the anti-aging steamed bread is enhanced.

The present invention provides a novel conjugate comprising an antibody directed toward a cell surface associated antigen, wherein said antigen is selected from the group consisting of 15A8 antigen and ZME-018 antigen; and a biological response modifier moiety, wherein said moiety is selected from the group consisting of TNF-alpha, TNF-beta and Interleukin-1. In addition, the present invention also provides a method of treating proliferative cell diseases comprising administration of a cytocidally effective dose of the composition of claim 1 to an individual in need of said treatment.

A novel architecture solid-state biosensor for label-free detection of vascular endothelial growth factor (VEGF) hybridization is presented. The new device is realized by forming a matrix array of parallel capacitors, thus allowing the realization of low-cost, portable, fully integrated devices. The detection mechanism is based on an electrochemical binding of circulating VEGF to an immobilized VEGF aptamer; whereby binding of these two compounds modulates the threshold voltage of a novel circuit, changing the impedance (capacitance) of the circuit. This novel circuit is further characterized by an electrode coded with a p-Si substrate, enhancing the affinity between the VEGF molecules and the aptamer. An apparatus forming a fluid cell is configured so as to enable the flow for delivering VEGF samples onto the active surface of the chip. The device has an array of parallel capacitors which act as an integrated, individual counter-electrode, computational apparatus which employs the sensory output over the time domain so as to enable detection, reporting and formation of a homeostatic loop for VEGF measurements. Moreover, this detector is able to provide an accurately measured and quantifiable rate of change of the VEGF molecules in-vivo, providing real time feedback of this important biomarker which may be used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden.

The invention discloses a nervonic acid composition. A main component of the nervonic acid composition comprises nervonic acid, and an oligosaccharide or beta-glucan; the oligosaccharide is one selected from isomalto oligosaccharide, fructose oligosaccharide or lactose oligosaccharide, xylose oligosaccharide or soybean oligosaccharides. The ingredients above are uniformly mixed so as to obtain a mixture, and the mixture is prepared into tablets, capsules or powder. In addition, natto powder or natto kinases is also added. The nervonic acid composition is capable of promoting neural restoration and brain nourishing effects of nervonic acid; and the oligosaccharide possesses unique biological activity as a functional factor, is capable of preventing tumor and imflammation, and reducing blood fat, and can be used as an immunomodulator. The ingredients are biological response modifiers (BRMs); are healthy food capable of conditioning intestines and stomach functions; possess antibacterial actions; are capable of conditioning intestines and stomach, relaxing bowel, eliminating toxin and beautifying skin; are not influenced by strong acidity of gastric juice; and are capable of realizing colonization in intestinal tract. In addition, nutritional additives and disease-resistant additives with better effects can be obtained via combination of the nervonic acid composition with immune complexes capable of penetrating gastric shield.

An enhancer, for treatment of lymphocytic tumors, of an antibody that specifically binds to protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity, said enhancer comprising a biological response modifier as an active ingredient.

A compound for use in a method of treatment of cancer, including precancerous lesions, and adverse events caused by the disease or anti-cancer agents and treatments, such as cancer cachexia, lymphopenia, neutropenia, febrile neutropenia includes in combination an immunomodulatory and at least one anti-cancer agent or treatment suitable for treating the disease. The immunomodulator is a proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride. The anti-cancer agent or treatment suitable for treating the disease provides synergistic effects without additional toxicity when used with the immunomodulatory. The anti-cancer treatment is selected from the following group: surgical procedures, transplantation of bone marrow cells, systemic and localized radiotherapy, and combinations thereof.

An embolization device which is placed at a definite position in a vessel cavity in vivo to embolize the vessel cavity. More specifically speaking, an embolization device to be used for plugging a blood vessel or a aneurysm formed in a blood vessel. After being placed in a vessel cavity in vivo, this embolization device promotes not only thrombosis but also organization over the surrounding area, thereby exerting an excellent embolization effect on the vessel cavity. Namely, an embolization device for plugging a vessel cavity in vivo characterized by having biological response modifiers (BRM) which can promote organization and exert an enhanced embolization effect after being placed in a vessel cavity in vivo.

This invention relates to a novel Biomolecule Transduction Motif (BTM), Mph-1 peptide, which has the potential to transduce many biological response modifiers effectively into the cytoplasm, intracellular organelles or nucleus of prokaryotic or eukaryotic cells in vivo and in vitro, and the related technological methods using Mph-1 BTM. This Mph-1 BTM can be used in the development of new recombinant protein vaccines or DNA / RNA vaccines, gene and protein therapy, production of pharmacologically or medicinally useful proteins, or pharmaco-medicinal drug therapy.

The present invention provides anticancer biological response modifier for the treatment of cancer. In accordance with an aspect of the present invention, there is provided a composition for the treatment of breast and prostate cancer in a mammal, said composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: is extracted from bile of animals; is capable of stimulating monocytes and / or macrophages in vitro and / or in vivo; is capable of modulating tumor necrosis factor production and / or release; contains no measurable level of IL-1α, IL-1β, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-gamma; is not cytotoxic to human peripheral blood mononuclear cells; is not an endotoxin; and optionally with (ii) one or more anticancer agent(s), wherein said combination has therapeutic synergy or improves the therapeutic index in the treatment of cancer over the composition or the anticancer agent(s) alone. Another aspect of the present invention provides the use of this composition or combination in the manufacture of a medicament for the treatment of breast or prostate cancer in a mammal.

A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and / or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others.

The invention relates to a lentinan lyophilized power injection and a preparation method thereof, belonging to the technical field of biological response modifier antitumor drugs. The lentinan lyophilized power injection is characterized in that the injection comprises 0.95-1.10 parts of lentinan and 1-33.5 parts of excipient by weight, wherein the weight mean molecular weight of lentinan is 400-800 thousands, the content of the components with more than 20 thousands is not less than 98wt% and the content of the components with more than 2000 thousands is less than 2wt%, the invention has the advantage that salt-free technology is used in the preparation method of the lyophilized preparation and water for injection is used for direct dissolution in the preparation of the injection. The salt-free preparation can reduce the adverse reaction of patients and improve the safety of medication. The invention ensures the curative effect of lentinan, reduces the poison and side effect, increases the safety and reduces the production cost and the preparation method is simple and is applicable to scale industrialized production.

A bcg polyoses nucleic acid intralipid and its freeze dehydration agent and purpose are provided. The proportion for the weight shares of intralipid is: bcg polyoses nucleic acid of 0.05 to 0.5 per cent, oily component of 4 to 8 per cent, emulsifier of 3 to 8 per cent and water of 84 to 92 per cent. The oily component refers to one or more than one from plant oil, animal oil, neutral lipids, synthetic grease, sterol derivative; the emulsifier refers to the normative emulsifier in making medical preparation with the pH value of preparation liquid of 6.5 to 7.5; freeze and dry the intralipid under normal condition to make freeze dehydration agent. The invention can be applied as therapeutic agent for resisting cancer, intra-cellular infection, hypersusceptibility, cold and asthma. In the invention, the biologic reaction regulator of bcg polyoses nucleic acid is prepared as a lymph targeting preparation that can effectively regulate immunity, resisting cancer, intra-cellular infection, hypersusceptibility, cold and asthma with high efficiency and without toxic content.

A novel architecture solid-state biosensor for label-free detection of vascular endothelial growth factor (VEGF) hybridization is presented. The new device is realized by forming a matrix array of parallel capacitors, thus allowing the realization of low-cost, portable, fully integrated devices. The detection mechanism is based on an electrochemical binding of circulating VEGF to an immobilized VEGF aptamer; whereby binding of these two compounds modulates the threshold voltage of a novel circuit, changing the impedance (capacitance) of the circuit. This novel circuit is further characterized by an electrode coded with a p-Si substrate, enhancing the affinity between the VEGF molecules and the aptamer. An apparatus forming a fluid cell is configured so as to enable the flow for delivering VEGF samples onto the active surface of the chip. The device has an array of parallel capacitors which act as an integrated, individual counter-electrode, computational apparatus which employs the sensory output over the time domain so as to enable detection, reporting and formation of a homeostatic loop for VEGF measurements. Moreover, this detector is able to provide an accurately measured and quantifiable rate of change of the VEGF molecules in- vivo, providing real time feedback of this important biomarker which may be used to measure response of the tumor to delivered chemotherapeutic agents and biological response modifiers (BRMs) for the purpose of determining tumor burden.